Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

VX-787 is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. Viral genetics and X-ray crystallography studies provide support for the idea that VX-787 occupies the 7-methyl GTP (m(7)GTP) cap-binding site of PB2. VX-7...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Byrn, Randal A., Jones, Steven M., Bennett, Hamilton B., Bral, Chris, Clark, Michael P., Jacobs, Marc D., Kwong, Ann D., Ledeboer, Mark W., Leeman, Joshua R., McNeil, Colleen F., Murcko, Mark A., Nezami, Azin, Perola, Emanuele, Rijnbrand, Rene, Saxena, Kumkum, Tsai, Alice W., Zhou, Yi, Charifson, Paul S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2015
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4325764/
https://ncbi.nlm.nih.gov/pubmed/25547360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04623-14
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge